Evidence map›Paper›PMID 40186067›Full record

ArticleJournal of neurology2025

Rate of change in upper and lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis.

A Maranzano, F Gentile, M Passaretti, A Doretti, E Colombo, A K Wall, M Treddenti, V Patisso, A De Lorenzo, C Gendarini and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

A MaranzanoUnit of Neurology, Department of Neurosciences, IRCCS Istituto Auxologico Italiano, Milan, Italy. a.maranzano@auxologico.it.ORCID http://orcid.org/0000-0002-3642-9584
F GentileDivision of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
M PassarettiDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
A DorettiUnit of Neurology, Department of Neurosciences, IRCCS Istituto Auxologico Italiano, Milan, Italy.
E ColomboUnit of Neurology, Department of Neurosciences, IRCCS Istituto Auxologico Italiano, Milan, Italy.
A K WallUnit of Neurology, Department of Neurosciences, IRCCS Istituto Auxologico Italiano, Milan, Italy.
M TreddentiNeurology Residency Program, Università degli Studi di Milano, Milan, Italy.
V PatissoNeurology Residency Program, Università degli Studi di Milano, Milan, Italy.
A De LorenzoNeurology Residency Program, Università degli Studi di Milano, Milan, Italy.
C GendariniNeurology Residency Program, Università degli Studi di Milano, Milan, Italy.
A CocuzzaNeurology Residency Program, Università degli Studi di Milano, Milan, Italy.
A D MaioNeurology Residency Program, Università degli Studi di Milano, Milan, Italy.
S PierroNeurology Residency Program, Università degli Studi di Milano, Milan, Italy.
B PolettiUnit of Neurology, Department of Neurosciences, IRCCS Istituto Auxologico Italiano, Milan, Italy.
C M CinnanteSection of Neuroradiology, Department of Radiology and Diagnostic Imaging, IRCCS Istituto Auxologico Italiano, Milan, Italy.
C MorelliUnit of Neurology, Department of Neurosciences, IRCCS Istituto Auxologico Italiano, Milan, Italy.
S MessinaUnit of Neurology, Department of Neurosciences, IRCCS Istituto Auxologico Italiano, Milan, Italy.
J B PereiraDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
O HardimanAcademic Unit of Neurology, Trinity College Dublin, Dublin, Ireland.
V SilaniUnit of Neurology, Department of Neurosciences, IRCCS Istituto Auxologico Italiano, Milan, Italy.
F Verde *Unit of Neurology, Department of Neurosciences, IRCCS Istituto Auxologico Italiano, Milan, Italy.
N Ticozzi *Unit of Neurology, Department of Neurosciences, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Funding

Ministero della Salute 2022-12375731Ministero della Salute E3-2022-23683266
6 · The paper itself

Abstract

backgroundWe hypothesize that the rate of change in upper (ΔUMN) and lower (ΔLMN) motor neuron signs from symptom onset to first clinical assessment represent best predictors of survival and disease progression in amyotrophic lateral sclerosis (ALS) compared to singular quantification of UMN and LMN involvement.

methodsA retrospective inpatient cohort of 1000 ALS patients was evaluated. The burden of UMN and LMN signs was assessed using the Penn Upper Motor Neuron Score and Lower Motor Neuron Score, respectively. For 421 patients, we compute the ENCALS survival model. Univariate and regularized Cox regressions were conducted to estimate the effect of the aforementioned variables on survival. The ROC curve analysis was then employed to a training sub-cohort to identify a ΔLMN cut-off value discriminating ALS patients with prolonged vs short survival. This cut-off value was then cross validated on a test sub-cohort. A multinomial regression model was used to compare different ΔUMN and ΔLMN scores among ENCALS groups.

resultsΔUMN and ΔLMN showed a negative association with survival (ΔUMN: HR = 1.30; ΔLMN: HR = 4.22). A cut-off value of 0.22 for ΔLMN was identified to predict patients with estimated short vs prolonged survival. ENCALS groups characterized by shorter survival presented significantly higher ΔUMN and ΔLMN scores compared to those with longer survival. No significant association of PUMNS or LMNS gross scores with the above-mentioned variables was observed.

conclusionBy reflecting the progressing degeneration of the two distinct motor neuron subpopulations, ΔUMN and ΔLMN might represent reliable and easily measurable clinical indexes to estimate survival in ALS.

Indexed as

Amyotrophic Lateral SclerosisMotor NeuronsAdultAgedCohort StudiesDisease ProgressionFemaleHumansMaleMiddle AgedRetrospective StudiesROC CurveSeverity of Illness IndexAmyotrophic lateral sclerosisMotor indexesPrognosisSurvival

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.